NCT03355014View on ClinicalTrials.gov

BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

January 12, 2018

Study Completion Date

January 12, 2018

Conditions
Healthy Male Volunteers
Interventions
DRUG

Combination of gemigliptin/metformin HCl sustained release 50/1000mg

Gemigliptin/Metformin HCl extended release 25/500mg 2tablets

DRUG

Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg

Zemiglo 50mg 1 tablet Glucophage XR 2 tablets

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

LG Chem
All Listed Sponsors
lead

LG Chem

INDUSTRY

NCT03355014 - BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone | Biotech Hunter | Biotech Hunter